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Fluorescence studies of the binding of amphiphilic
amines with phospholipids
Jane Y. C. Ma,’ Joseph K. H. Ma,** and Kenneth C. Weber’”
NIOSH* and the School of Pharmacy, West Virginia University,** Morgantown, West Virginia 26505

Abstract The binding characteristics of several amine drugs
with dispersed phospholipids (phosphatidylcholine, phosphatidylserine, and phosphatidylglycerol) have been studied using the
fluorometric method and l-anilino-8-naphthalene sulfonate and
as fluorescence probes. The results
1,6 diphenyl-1,3,5-hexatriene
show that amphiphilic amines, such as chlorphentermine, interact with phospholipids via both ionic and hydrophobic forces.
The ionic interaction, which occurs between the protonated
amine group of the drug and the phosphate oxygen of the lipid,
changes the amphiphilic characteristics of the lipid by reducing
the number of negative charges on the lipid vesicles, and inhibits
the Caw-dependent lipid hydrolysis by blocking the Car binding sites on the lipid vesicles. The hydrophobic interaction,
which involves the nonpolar moieties of the drug and the lipid,
is of primary importance to the overall drug-lipid binding stability. Drugs without a strong hydrophobic moiety, such as
dopamine, do not interact with phospholipids. Ma, J. Y. C.,
J. K. H.Ma, and K. C. Weber. Fluorescence studies of the
binding of amphiphilic amines with phospholipids. J Lipid h.
1985. 26: 735-744.
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Cationic amphiphilic drugs such as chlorphentermine
and imipramin have been shown to cause phospholipid
storage disorders in rat lungs characterized by the
accumulation of large, phospholipid-laden alveolar macrophages (1-4). In a study of the pharmacokinetics of
phentermine and chlorphentermine in rats, Liillmann,
Rossen, and Seiler (5) demonstrated that the druginduced lipidosis may be directly related to the tissue concentration of the drug. Their results show that phentermine, which does not induce lipidosis, is more readily
eliminated from tissues than is chlorphentermine in rats
treated with a single dose. The results also show that in
chronically treated rats there is a steady increase in tissue
accumulation of chlorphentermine but not phentermine,
suggesting that the binding of the amphiphilic drug to the
tissue components, or perhaps to phospholipids, may be
required in order to produce lipidosis.
In the attempt to further elucidate the mechanism of
the drug-induced lipidosis, several studies dealing with

drug-lipid interactions have been reported. Liillmann,
Liillmann-Rauch, and Wassermann (6,7) proposed that
the cationic amphiphilic amines interact with phospholipids via both electrostatic and hydrophobic forces, and
that such binding may lead to impaired lipid metabolism
by changing the physicochemical properties of the lipids
such that they become less readily attacked by phospholipases. Indeed, a study by Grabner (8) has shown that
chlorphentermine inhibits the hydrolysis of phosphatidylcholine by bee venom phospholipase A*. The importance
of the hydrophobic interaction between the drug and
lipids has been demonstrated by Seydel and Wassermann
(9, 10). They found that several amphiphilic drugs
including chlorphentermine, but not phentermine, are
capable of binding with phosphatidylcholine and phosphatidylethanolamine via hydrophobic interaction between the nonpolar moieties of the drugs and the lipids.
They further showed that drugs such as chlorphentermine
do not bind appreciably with pancreatic phospholipase
A*, suggesting that the drug-lipid interaction may be
directly responsible for the inhibition of phospholipid
catabolism.
To provide more insight as to the nature of the druglipid interactions and the mechanism of drug inhibition of
phospholipid catabolism, we have carried out binding
studies of phospholipids with several amine drugs of
varying amphiphilic characteristics by using a fluorometric technique with l-anilino-8-naphthalenesulfonate
(ANS) and 1,6-diphenyl-1,3-5-hexatriene
(DPH) as fluorescence probes. Phospholipids are amphiphilic molecules that consist of a hydrophilic phosphate head group
and long aliphatic chains that are hydrophobic in nature.
The phosphate moiety exhibits a negatively charged
-

Abbreviations: ANS, 1-anilino-8-naphthaleneaulfonate;DPH, 1,6diphcnyl-1,3,5-huratriene;DPPC, dipalmitoylphasphatidylcholine (1,2dipalmitoyl-m-glycero-3-phoaphocholine);LPC, lyaophosphatidylcholine (l-palmitoyl-m-glycero-3-phosphocholine);PS, phoaphatidylserine;
DPPG, 1,2-dipalmitoyl-m-glycero-3-phmphogl~erol.
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oxygen group which is capable of interacting with cationic
species. Thus, it is not surprising that phospholipids
exhibit strong affinity for the highly cationic amphiphilic
amines. ANS is an anionic fluorescent agent which has
been shown to be a valuable probe for the study of lipid
interactions involving the hydrophilic phosphate moiety
(11, 12). DPH, which has been shown to bind to the
interior of the lipid vesicles (13-15), is used as a probe to
characterize the hydrophobic interaction between the
cationic amphiphilic amines and phospholipids.

348 nm; emission 422 nm) obtained from Atarna Scientific, Ltd., Swarthmore, PA. Unless otherwise mentioned, the temperature of the fluorometer cell compartment was controlled for all experiments at 25 f 0.1OC
using a circulatory water bath from Forma Scientific, Inc.,
Marietta, OH.

Fluorometric binding studies

Binding studies of the amphiphilic amines with phospholipids were carried out in 0.01 M Tris buffer (pH 7.0)
using a fluorescence probe technique. To characterize the
hydrophobic interaction between the amines and phospholipids, DPH was used as a fluorescence probe. The
EXPERIMENTAL
lipid-bound DPH shows intense fluorescence at 440 nm
(excitation, 368 nm), while the non-bound DPH does not
Materials
exhibit fluorescence in aqueous solution. Studies of the
The fluorescence probes, 1-anilino-8-naphthalene suldrug-lipid interaction using DPH as a probe were based
fonate (ammonium salt; ANS) and 1,6-diphenyl-1,3,5- on a competitive binding mechanism in which the
hexatriene (DPH), were obtained from Aldrich Chemical
quenching of DPH fluorescence by the addition of drug
Co. (Milwaukee, WI) and from Molecular Probes, Inc.
was assumed to be due to the binding of the drug at or
(Junction City, OR), respectively. Dopamine hydrochlonear the DPH binding sites on the lipid. For the study of
ride, ephedrine hydrochloride, and phenylpropanolamine
the ionic interaction between the drugs and phosphohydrochloride were purchased from Sigma Chemical Co.
lipids, ANS was used as the fluorescence probe. The
(St. Louis, MO), and the hydrochloride salts of chlorrelative binding strength of the drugs was evaluated based
phentermine and phentermine were kindly supplied by
on the effect of the drugs on the binding of ANS to the
Dr. M. Reasor of the Department of Pharmacology, West
lipids.
Virginia University School of Medicine. Phospholipase
Binding studies using DPH as. a probe. Stock solutions of
A2 from bee venom was obtained from Sigma Chemical
DPH in tetrahydrofuran
M) were freshly prepared
Company. The chloride salts of Ca2*, Ba2+, and Mg"
and protected from light exposure. To determine the bindwere obtained from Fisher Scientific Company.
ing of DPH to DPPC, samples containing a constant
The synthetic 1,2-dipalmitoyl-sn-glycero-3-phosphocho- concentration of DPPC and various concentrations of
line (DPPC) and 1-palmitoyl-sn-glycero-3-phosphocholine DPH in the range of 5 x 10-8-5 x IOw6M were incubated
(LPC) were obtained from Calbiochem-Behring Corp.
at 5OoC for 60 min. After the samples were allowed to cool
The synthetic 1,2-dipalmitoyl-sn-glycero-3-phosphoglyc- to room temperature, 2 ml was used for measurement of
erol (DPPG) and phosphatidylserine (PS) from bovine
fluorescence intensity. The fluorescence was then plotted
brain were obtained from Avanti Polarlipids, Inc. The
as a function of DPH concentration. This experiment was
phospholipid vesicles dispersed in (0.01 M) Tris buffer
repeated using different lipid concentrations. When the
(pH 7.0) were prepared by sonication of lipid solutions
DPPC concentration was
M or above, the fluoresunder nitrogen using a heat system W375 sonifier. Samcence was found to be linear with DPH concentration,
ples of DPPC and DPPG were sonicated for 30 min at
suggesting that all DPH molecules in the solution are in
5OoC, whereas samples of PS were sonicated for 10 min
the bound form. These data were used to calculate the
at 4OC. Small vesicles of these solutions were fractionated
bound and free concentrations of DPH in a solution of
from the larger liposomes by centrifugation at 105,000 g
lower DPPC concentration (
M); i.e., the fraction of
for 60 min. The concentration of phospholipids was
bound-DPH in the solution of lower DPPC concentration
determined by measuring the inorganic phosphorus using
was taken to be the ratio of its fluorescence with that of
the method of Bartlett (16).
the solution containing loe3 M DPPC at the same total
concentration of DPH.
Instruments
The binding constant and the binding capacity between
DPH (probe) and DPPC vesicles were determined
The fluorescence measurements were carried out using
using
equation
1, assuming equal binding strength for all
an Aminco-Bowman spectrophotofluorometer (American
binding
sites
(Scatchard
equation):
Instrument Co., Silver Spring, MD) equipped with a 150
W Xenon lamp, a 1P21 photomultiplier tube, and an X-Y
V
-=nK-vK
Eq. 1 )
spectral recorder. Standardization of the fluorescence
[PI
intensity of the instrument was routinely carried out
where v is the number of moles of bound probe per mole
using a solid sample of tetraphenylbutadiene (excitation,

-
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of lipid; [PI is the free concentration of the probe, DPH;
n is the maximum value of v which indicates the binding
capacity of the lipid for DPH; and K is the binding
constant. For the competitive binding studies, fluorometric titrations of solutions containing 5 x lO-5 M DPPC
and a constant concentration of DPH with stocksolutions
of the amine drugs were performed, and the quenching of
the fluorescence was recorded as a function of drug concentration. The fluorescence data were used to calculate
the free and bound concentrations of DPH in the presence of the drug. Among the drugs used inthis study, only
chlorphentermine exhibited a significant effect on the
fluorescence of lipid-bound DPH at room temperature.
The binding of chlorphentermine to DPPC was determined using equation 2. This equation was derived from
the competitive binding mechanism assuming that the
drug competes for nl of the n probe binding sites with an
intrinsic binding strength of K1:
(n - vl)vl
(n - v* - vi) [Dl

=

nlKl - vlKl .

Eq. 2)

In this equation, v* is the ratio of bound-probe per total
lipid concentration in the presence of drug; v1 is the ratio
of bound-drug per total lipid concentration; nl is the
maximum value of v1 which indicates the probe binding
sites which may be replaced by drug binding; [Dl is the
free drug concentration; and K1is the binding constant
for the drug-lipid interaction. The term n has been previously defined. For the calculation of nl and K1using
equation 2, v8 was determined from the fluorescence
data, whereas v1 was calculated from equation 3, after n
and K had been determined using equation 1 :
vl=n-v*--

V*

Eq. 3)

[P]*K .
The term [PI* represents the free concentration of the
probe. in the presence of drug. After v1 was determined,
[Dl was taken to be the difference betweenthe total drug
concentration and the product of vi and total lipid
concentration.
Binding studies using ANS as a pmbe. ANS exhibits weak
fluorescence at 510 nm (excited at 380 nm) in aqueous
solution alone, but shows enhanced fluorescence intensity
at 480 n m (excited at 380 nm) when bound to DPPC. The
fluorescence of the lipid-bound ANS was further increased by the addition of amphiphilic drugs, suggesting
the formation of a drug-lipid-ANScomplex
in the
ternary system. To evaluate the binding phenomena, the
emission coefficient(A) of the different speciesof ANS, at
480 nm delined as the fluorescence intensityhpecies concentration ratio, was determined.
For the binary ANS-lipidsystem, fluorometric titrations of solutions containing a constant concentration of
phospholipid with a stock solution of ANS were carried

out at several lipid concentrations. At relativelyhigh
concentrations of lipid (1 x lo-’ M) and low concentration of ANS (in the order of 10-7-10-6 M), the titration
showed a linear relationship between fluorescence intensity and ANS concentration. The slope of the linear plot
was taken to be the emission coefficientof the binary ANS
complex (Ab). The binding of ANS to phospholipid was
determined using solutions containing 2 x lO-5 M lipid
and varying concentrations ofANS.
The fraction of
bound ANS, x,, inthese solutions was calculatedaccording to the following equation:
x
b =

(Fb - Fo)/(Ab - Ao)

Eq, 4 )

where Fb and Fo are the fluorescence intensities for sohtions with and without lipid, while & and & are the
emission coefficients for the lipid-bound and free ANS,
respectively. The values ofA, and Ab for DPPC at 480
nm were determined to be 0.5 x lo6 and 68 x lo6,
respectively. From the value of x,, the concentrations of
free and bound ANS were calculated for each solution
and the data were treated using equation 1.
In the ternary system, fluorometric titrations of solutions containing 1O-2 M drug and constant concentration
of phospholipid witha stock solutionof ANS were carried
out at several lipid concentrations. The drug concentration of 1O-2 M was found to be sufficient to saturate the
lipid’s drug-binding sites. At the relatively high concentration of lipid (1 x lo-’ M) and low concentrations of the
probe, the plot of fluorescence intensity versus ANS concentration was linear, and the slope of the linear plot was
then taken to be the emission coefficientof the ternary
ANS complex (At). For the quantitative determination of
the binding of ANS to lipid saturated with drug binding,
a solution containing 2 x lO-5 M lipid and U T 2 M drug
was titrated with a stock solution of ANS and the fluorescence of each titration increment was measured. The free
and bound concentrations of ANS corresponding to each
total ANS concentration along the titration curve were
calculated using A, in the same manner as described for
the binary system. The binding parameters were then
determined using equation 1. In thissystem,since the
fluorescence change is due to the formation of the druglipid-ANS ternary complex, the value of n should also
indicate the binding capacity of the lipid for the amphiphilic drug.
RESULTS AND DISCUSSION
The binding nature of amphiphilic amines
with phospholipids
ANS, a relatively
nonfluorescent
molecule,
shows
intense fluorescencewith a blueshift of its emission
maximum when bound to macromolecules capable of
providing a hydrophobic environment (17). Studies have
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shown that ANS binds to phospholipids in such a way that
the anionic sulfonate group is oriented toward the hydrophilic head group of the lipid (11, 12, 18). Due to ionic
interaction leading to charge neutralization, such binding
and the fluorescence enhancement are obviously stronger
for lipids possessing a non-hindered positive nitrogen
such as DPPC. Phospholipids contain a negative phosphate oxygen group at physiological pH. Thus, further
enhancement of the fluorescence of lipid-bound ANS may
be brought about by the addition of cationic species
capable of binding to the negative oxygen group. The
effects of two cationic species, Ca2+ and chlorphentermine, on the fluorescence of DPPC-bound ANS are
shown in Fig. 1. Both Caz+ and chlorphentermine increase the fluorescence of DPPC-bound ANS, suggesting
that these ions interact with the negative phosphate
oxygen group and provide a more hydrophobic environment in the vicinity of the ANS molecule. The results also
show a greater fluorescence enhancement for the monovalent chlorphentermine ion than that for the divalent
Ca2+.The negative phosphate oxygen group of the lipid
as a binding site for Ca2+has been well established in
several studies (11, 12).
The effects of chlorphentermine on the fluorescence of
DPPC, DPPG, and PS-bound ANS are shown in Fig. 2.
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Fig. 2. Plots of fluorescence intensity, F-Fo, as a function of lipid concentration for solutions containing 5 x lO-5 M ANS and varying concentrations of lipids (circles, DPPC; triangles, PS; squares, DPPG) in
the absence (open symbols) and presence (fdled symbols) of lo-' M
chlorphentermine. F-Fo is the difference in fluorescence between the
above solutions and the solution of 5 x 10'' M ANS. The drug and ANS
concentrations used are sufficiently high to saturate the lipid binding
sites, so that the value, F-Fo, is proportional to the concentration of lipidbound ANS. The fluorescence intensity was measured at 480 nm with
excitation at 380 nm.
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Fig. 1. Fluorescence spectra of solutions containing 5 x lO-5 M ANS
(A) and in the presence of B) 9.36 x 1O-6 M DPPC, C) 9.36 x 1O-6 M
DPPC, and lo-' M Ca", and D) 9.36 x lo-6 M DPPC and lo-' M chlorphentermine in pH 7.0, 0.01 M Tris buffer. The spectra were obtained
with an excitation at 380 nm. In the absence of DPPC, CaZ+or chlorphentermine did not show significant effects on the ANS spectrum.
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The binding of ANS with DPPG and PS did not result in
a significant increase of ANS fluorescence probably due
to the lack of a non-hindered positive nitrogen group in
these lipids. However, strong fluorescence enhancement
was observed when the system contained chlorphentermine. The results further suggest that chlorphentermine
interacts with the negative oxygen group of the lipid's
phosphate moiety.
The ionic interaction of phospholipids is of significant
consequence to the lipid's solubility and surface activity.
At high concentrations of lipid and ANS, addition of
chlorphentermine results in a precipitation of the lipid
due to charge neutralization and the subsequent loss of its
amphiphilic characteristics.
DPH is a nonfluorescent molecule in aqueous solution,
but is known to bind to the interior of lipid vesicles and
gives intense fluorescence at 440 nm (13-15). The effect of
chlorphentermine on the binding of DPH to DPPC
vesicles at room temperature and at 45OC is shown in

Fig. 3. The addition of chlorphentermine quenches the
fluorescence of the lipid-DPH solution, probably indicating a binding displacement of DPH by chlorphentermine which binds in close proximity to the DPH binding
sites. This quenching effectis much greater at a temperature above the transition temperature of the lipid (45OC)
than at lower temperature (25OC), suggesting that the
amphiphilic drug exhibits only a limited penetration of
the interior of the lipid vesicles, i.e., the binding of chlorphentermine affects only those DPH binding sites near
the vesicel surface. Nevertheless, these results show a
second binding mode for the drug-lipid interaction which
involves the hydrophobic interaction between the nonpolar moieties of the two species.
Hydrophobic interactions are important to the overall
binding of drugs to phospholipids. Table 1 shows the
effect of several amine drugs of varying amphiphilic
properties (as indicated by their structures) on the fluorescence of DPPC-bound ANS. The value At/Ab represents
the fluorescenceenhancement of the ternary complex over
the binary complex. It can be seen that dopamine, which
is not amphiphilic in nature due to the presence of the
catechol group in their hydrophobic moiety, shows little or
no interaction with DPPC. On the other hand, relatively
strong amphiphiles, such as phentermine and chlorphen-

termine, exhibit relatively strong interactions with phospholipid.
The above results show a binding nature between the
drug and lipid that is consistent with the amphiphilic
characteristics of both species, i.e., the binding involves
both hydrophobic and ionic interactions. The results indicate that, while the ionic interaction is most likely a cause
for drug effect on surface activity of phospholipids, the
hydrophobic interaction may serve as a stabilizing force
for the binding of drug to lipid vesicles. One may consider
that the hydrophobic interaction provides an orientation
of the two species such that the ionic interaction is possible.
Quantitative aspects of the drug-lipid interaction

A Scatchard plot (equation I) for the binding of DPH
to DPPC at 25OC is shown in Fig. 4. From the straight

line plot, the values of n and K were calculated to be
0.0167 and 2.85 x IO6 W, respectively. These results
suggest a strong hydrophobic binding between DPH and
DPPC with a binding ratio of 1 DPH molecule per 60
lipid molecules. Since the number of lipid molecules per
vesicle in unknown, the number of binding sites per lipid
vesicle was not calculated. A plot that illustrates the
competitive binding between chlorphentermine and DPH
to DPPC (equation 2) is shown in Fig. 5. The plot shows
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Fig. 3. EBect of chlorphentermine on the binding of DPH to DPPC at 25OC (circles) and at 45OC (stars) as indicated by fluomcnce quenching. All solutions contain 5 x lom5M DPPC, a constant concentration of DPH, and
varying concentrationsof chlorphentermine (A: 5 x lo-’ M; B: 8 x lo-’ M; C: 5 x lo-’ M; D 1.0 x 1O-6 M). Fluorescence measurements were made at 440 nm with excitation at 368 nm.
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TABLE 1. Chemical structure of selected amines and their effect on the fluorescence of DPPC-bound ANS

*@
3
2
Ring

Dopamine
Phenylpropanolamine
Ephedrine
Phentermine
Chlorphentermine

3-OH,4-OH

4-C1

P

CH-

a
C

P

a

Amino

AJA;

H
OH
OH
H
H

H,H
H,CHs
H,CHJ
CHs,CHs
CHs,CH,

H
H
CHI
H
H

1.o
1.50
1.45
3.70
7.09

-N H

*Atand Ab are the emission coefficients of ANS in the ternary (drug-lipid-ANS) and in the binary (lipid-ANS)
complexes, respectively.

a straight line from data obtained in three separate
experiments, and gives a value of 0.004 for nl and 8.04
x lo3 M-’ for K1. These results suggest that about onefourth of the bound DPH may be replaced by the binding
of chlorphentermine. The relatively weak hydrophobic
binding strength as indicated by K1 suggests that these
binding sites are near the surface of the lipid vesicles.
Other amine drugs used in this study, which are less
amphiphilic than chlorphentermine, did not quench the
fluorescence of lipid-bound DPH.
The Scatchard plot for the binding of ANS to DPPC is
shown in Fig. 6. From the slope and the intercept of the
plot, the values of n and K were calculated to be 0.034 and
1.4 x lo5 M-’, respectively. These results indicate a strong
binding between the probe and the lipid with a molar

Fig. 4. Scatchard plot (equation I) for the binding of DPH to DPPC
at 25OC measured at two lipid concentrations (0 5 x lo-’ M; 0
2 x 10-5 MI.
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binding ratio of about 1:30 (ANS:DPPC). The binding of
the anionic probe to either PS or DPPG was not indicated
by the fluorometric method, probably because these lipids
exhibit an overall negative charge on the phosphate
moiety at neutral pH. In the ternary systems, however,
the anionic probe was found to interact with all three
phospholipids. The results are shown in Fig. 7, where the
binding data for solutions containing lo-* M chlorophentermine, 2 x lO-5 M lipid, and varying concentrations of
ANS are treated with equation 1. The data for the ANS-

Fig. 5. Binding of chlorphentermine to DPPC measured by using
DPH as a probe (equation 2). Data were obtained from solutions containing 2 x io-’ M DPPC, varying concentrations of chlorphentermine
and 0 ) 5 x lo-’ M DPH; *) 8 x lo-’ M DPH; and 0 ) 2 x 1O-6 M
DPH.

Fig. 6. Scatchard plot for the binding of ANS to DPPC for solutions
containing 2 x lO-5 M DPPC and varying concentrations of ANS.

DPPC binding (curve A) shows a biphasic linear plot,
indicating that in the presence of chlorphentermine the
lipid has two classes of binding sites for the probe. At
relatively low ANS concentrations, the plot is linear and
gives a binding constant of 1.4 x lo5 M-'. This value is
the same as that calculated for the binary ANS-DPPC
binding, suggesting that the binding of the amphiphilic
drug does not affect the primary binding of ANS to the
lipid. However, the drug-lipid binding induces a secondary binding between the probe and the lipid as indicated
by the linear plot in the region of high ANS concentrations. In the cases of PS and DPPG, the linear plots
(curves B and C, respectively) show a single class of binding sites. Since the fluorometric method does not measure
the primary binding of the probe to PS and DPPG, these
data probably represent the drug-induced binding between the probe and the lipids. The overall binding
capacity, n, calculated from Fig. 7 for all lipids is 0.067,
which is twice the value calculated for the ANS-DPPC
binary system. The chlorphentermine effect may be
attributed to the ability of the cationic drug to neutralize
the negative charges of the lipid and thus create a condition more conducive for the probe binding. The additional binding capacity for the probe also reflects the
binding capacity of the lipid for the amphiphilic drug.
The effects Of Other amines On the binding Of ANS to
DPPC are shown in Fig. 8. For comparison, the solid line

Fig. 7. Effect of chlorphentermine on the binding of ANS to A) DPPC, B) PS, and C) DPPG. Data were obtained
from solutions containing 2 x lO-5 M lipid, IO-* M chlorphentermine, and varying concentrations of ANS and
treated using equation 1.
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Fig. 8. Effect of dopamine (a),phenylpropanolamine (O), ephedrine (*), and phentermine ( A ) on the binding
of ANS to DPPC. Data were obtained from solutions containing 2 x lO-5 M DPPC, lo-' M drug, and varying concentrations of ANS and treated using equation 1.

represents the binding plot for the ANS-DPPC binary
system. As can be seen, dopamine has no effect on the
ANS binding, suggesting that it does not interact with the
lipid. However, the binding of phenylpropanolamine,
ephedrine, and phentermine to DPPC is clearly indicated
by their ability to induce a secondary binding for ANS,
which occurs at relatively high ANS concentrations.
Based on their relative effects on the ANS-DPPC binding
shown in Figs. 7 and 8, it may be concluded that
these drugs interact with the lipid in the following
decreasing order of affinity: chlorphentermine > phentermine > ephedrine > phenylpropanolamine > dopamine.
Thus, although ANS is used to indicate the ionic
interaction of the amines with phospholipid, it shows that
the binding affinity of the amines to the lipid is closely
related to the hydrophobicity of the drug's nonpolar
moiety. The results on phentermine and chlorphentermine are consistent with those reported in the literature
(9, 10, 19).

Drug inhibition of DPPC hydrolysis by
phospholipase A2
Phospholipase A2 activity has been monitored using
ANS as a fluorescence probe. Fig. 9A shows the change
of ANS fluorescence as a function of time after the addition of 0.25 gg/ml of phospholipase A2 to a solution containing 1 x lo-5 M DPPC, 5 x lO-5M ANS, and 6 x lO-3
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M Ca2+.In the absence of the metal ion, the fluorescence
did not change as a function of time upon addition of the
enzyme. The enzymatic hydrolysis of DPPC into LPC is
indicated by the increase in ANS fluorescence and results
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Fig. 9. Fluorescence change (AF) as a function of time upon addition
of 0.25 pglml phospholipase A, to solutions containing 1 x lO-5 M
DPPC, 5 x lO-5 M ANS, 6 x lo-' M Ca", and in the absence (A) and
presence of 6 x lo-' M chlorphentermine (B). Drug inhibition of
enzyme activities is indicated by the reduction of fluorescence enhancement.

from the transformation of the Ca*+-DPPC-ANS complex into the Ca2'-LPC-ANS complex. The data shown
in Fig. 9 are consistent with literature results (20, 21). It
is also interesting to point out that the binding of ANS at
the phosphocholine nitrogen group of DPPC does not
appear to interfere with the enzymatic reaction, suggesting that the negative phosphate oxygen group of the lipid
is an important group in regulating the lipids activity.
Since the fluorescence studies indicate a binding of Ca2+
to phospholipid, it can be concluded that, in the presence
of enzyme, the formation of a ternary complex in which
Ca2+is linked to both the lipid and the enzyme is essential
for the enzymatic reaction.
Fig. 9B shows the effect of chlorphentermine on the
hydrolysis of DPPC by phospholipase A2, where the
inhibitory effect of the drug is demonstrated by the reduction of fluorescence enhancement. The results also indicate that the presence of chlorphentermine reduces only
the plateau level of the fluorescence intensity, but has no
effect on the rate of fluorescence enhancement, i.e., both
curves reach their plateau levels at approximately the
same reaction time. This suggests that chlorphentermine
affects mainly the binding equilibrium between c a 2 +and
the lipid that precedes the enzymatic hydrolysis reaction.
Further studies show that phentermine exhibits little or no
effect on the hydrolysis of DPPC by phospholipase A*,
indicating that only strong amphiphiles whose binding
with the lipid are significantly stabilized by hydrophobic
interactions are able to inhibit the enzymatic degradation
of phospholipids. Chlorphentermine possesses a stronger
hydrophobic moiety than phentermine, thus, exhibits
stronger binding. This may be the reason that, in chronically treated rats, large tissue accumulation was observed
for chlorphentermine but not for phentermine, and that
chlorphentermine, but not phentermine, induces lipidosis
( 5 , 22).

CONCLUSION
This study demonstrates that phospholipids bind with
cationic amphiphilic amines via both ionic and hydrophobic interactions. The ionic interaction occurs between
the protonated amine group of the drug and the negative
phosphate oxygen of the lipid, whereas the hydrophobic
interaction invovles the nonpolar moieties of both species.
The stronger hydrophobic interaction Of the two 'pecies
enhances the overall drug-lipid binding stability and thus
may play an important role in the drug-induced lipidosis.
The ionic interaction occurs only for amines possessing a
nonpolar moiety that is capable of binding with the lipid.
Our study shows a positive correlation between the
amphiphilic characteristics of the drugs and their binding
affinities. Drugs without a strong non-polar group, such
as dopamine, do not interact with the lipid. O n the other

hand, highly amphiphilic drugs, such as chlorphentermine, and to a lesser extent, phentermine, exhibit marked
ionic interaction with phospholipids.
Binding of amphiphilic amines has a direct effect on the
biological activities of the lipids. The ionic interaction of
strong amphiphiles can inhibit the metal ion-activated
enzyme degradation of phospholipids by blocking the
metal ion from binding to the lipid. Such inhibition may
be an important cause for the drug-induced lipidosis.
Furthermore, since the ionic interaction diminishes the
amphiphilic characteristics of the lipids, it is likely that
this interaction can also alter the physicochemical properties of the lipids and their surface activity. I
ManUcriptreceived 29 Octobu 1984.
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